Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2009
-
By Kevin E. Noonan — The Federal Circuit heard oral argument for In re Kubin last week, and a very hot bench (Judge Rader presiding, joined by Judges Linn and Friedman) sharply challenged the positions of both Kubin and the Patent Office. While it is foolish to attempt to read the tea leaves of…
-
By Donald Zuhn — Last week, we received a press release from PatentBuddy.com regarding an analysis of employment statistics performed by the patent networking website. PatentBuddy.com is an online database of patent attorneys and agents registered to practice before the U.S. Patent and Trademark Office. The website allows registered practitioners to create personal profiles…
-
By Donald Zuhn — Last week, Cytori Therapeutics, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 7,473,420. The '420 patent, which is directed to a method of treating patients with stem cells obtained from adipose tissue, is Cytori's sixth U.S. patent. The San Diego-based biotech company is also…
-
By Christopher P. Singer — The U.S. Patent and Trademark Office announced in a Notice posted on its website today that January 19th (Martin Luther King Day) and January 20th (Inauguration Day) are considered Federal holidays within the District of Columbia, under 35 U.S.C. § 21(b). Consequently, any action or fee due on either…
-
By Donald Zuhn — Last month, Medarex, Inc., Eurand, Inc., and Alexion Pharmaceuticals, Inc. joined the growing list of patentees that have filed complaints against U.S. Patent and Trademark Office Director Jon Dudas alleging that the Patent Office miscalculated the Patent Term Adjustment (PTA) for their patents. Medarex, Eurand, and Alexion became the eighth,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Eurand Inc. et al. v. Impax Laboratories Inc.1:09-cv-00018; filed January 7, 2009 in the District Court of Delaware Infringement of U.S. Patent…
-
January 12-13, 2009 – Pharmaceutical and Biotech Patent Opinion Writing*** (American Conference Institute) – San Diego, CA January 20-21, 2009 – Bio/Pharmaceutical Summit on Legal and Regulatory Product Lifecycle Strategies*** (Center for Business Intelligence) – Baltimore, MD January 26-27, 2009 – Structuring and Negotiating Pharma & Biotech Collaborative Agreements (C5) – London, England January 27-28,…
-
By Jason Derry — Endo to Acquire Indevus On January 5, 2009, Endo Pharmaceuticals Holdings Inc. announced that it will buy Indevus Pharmaceuticals Inc. for an initial payment of about $370 million and an additional $267 million, based on certain milestones. Currently, Indevus has marketed products for the treatment of overactive bladder, prostate cancer,…
-
By Christopher P. Singer — Given the recent news of Governor Bill Richardson's withdrawal from consideration as Commerce Secretary, and the impending resignation of U.S. Patent and Trademark Office Director Jon Dudas, the incoming administration may be giving renewed attention and interest to the Department of Commerce and the USPTO in particular. On December…
-
By Donald Zuhn — As we reported yesterday, the Federal Circuit heard oral argument today in In re Kubin (see "In re Kubin to Be Argued before the Federal Circuit on Thursday"). Kevin Noonan will be providing a complete analysis of the oral argument in this case in a subsequent post. One interesting aside,…
Patent Docs 